original articleshead and neck tumorsA randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
head and neck tumors
Under an Elsevier user license
open archive
Key words
PI3K
cetuximab
combination therapy
head and neck squamous cell cancer
PIK3CA
Cited by (0)
Copyright © 2015 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.